the purpose of this funding opportunity announcement (foa) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select niaid emerging infectious diseases/pathogens. applications must include a product development strategy attachment and demonstrate substantive investment by at least one industrial participant.

the specific objectives of this funding opportunity are:

• developing, testing, validating, scaling up and integrating innovative ict solutions for ageing well into re-designed service delivery models aimed at maintaining long term “functional ability” (see call rationale and who healthy ageing definition);
• contributing to the creation/strengthening/connection of healthy ageing ecosystems.

al call 2020 is part of the active & assisted living programme (aal programme) that was approved in may 2014 by the european parliament and the council of the european union. as part of the work programme, the aal programme has launched a new call for proposals in february 2020: “healthy ageing with the support of digital solutions.”

the aim of the call is to support innovative, transnational and multi-disciplinary collaborative projects. call 2020 is characterised by the following approach:

1. the aal call 2020 is open to developing ict-based solutions targeting any application area(s) within the aal domain. the solutions need to be embedded in the strategies of the participating end-user organisations, service providers and business partners.
2. the aal call 2020 allows for more flexibility regarding the scope, size and duration of the proposed projects (including small collaborative projects).

the aal domains include solutions for active living, such as in work & training, for vitality & abilities, in leisure & culture, for information & communication, as well as for assisted living, such as in health & care, living & building, mobility & transport, safety & security.

the government of canada is pleased to announce the launch of a new rapid research funding opportunity to continue to mobilize science to fight covid-19. this funding opportunity is a partnership between the canadian institutes of health research (cihr), the international development research centre (idrc), the michael smith foundation for health research, alberta innovates, the saskatchewan health research foundation, research manitoba, the new brunswick health research foundation, and research nova scotia, with additional potential partners to be confirmed.

objectives

• accelerate the availability of high-quality and real-time evidence to support canada’s rapid response to the global pandemic in order to better prevent, detect, treat and manage covid-19;
• develop, test, and study the implementation of effective interventions to prevent, detect, treat, and manage covid-19 at the individual and/or population levels by reorienting or amplifying existing research platforms, networks, and trials as well as funding new research projects within existing and established research infrastructure;
• enable canadian engagement and coordination in national and international large-scale trials and better enable harmonized data collection, sharing of data, quasi-experimental and observational studies, and rapid large-scale evaluation of impact;
• provide evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in canada and internationally; and
• enhance local, national and/or international collaborative efforts, including in low- and middle-income countries, to mitigate the rapid spread of covid-19 and related negative consequences.

funding will support clinical trials, observational studies, implementation science or other relevant study designs to scale-up promising existing projects, reorient current research, or initiate new rapid response research to address covid-19 in the identified research areas that include understanding the safety, efficacy, effectiveness, ethics, and implementation of:

• vaccines, diagnostics, or therapeutics;
• clinical management and health system interventions; and
• social, policy, and public health responses and related indirect consequences.

the fy20 defense appropriations act provides funding to the department of defense hearing restoration research program (hrrp) to support promising, necessary research for treatment of burdensome and very prevalent auditory system injury.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 hrrp program announcement and general application instructions for the following award mechanism will be posted on the grants.gov website.   

applications submitted to the fy20 hrrp must address one or more of the following focus areas:

• accelerate translation of biological regeneration/repair mechanisms into therapies that treat auditory system injury and restore auditory function.  for example, but not limited to:
  • hair cell regeneration/repair/recovery
  • neural regeneration/repair/recovery
  • treatment for synaptopathy and hidden hearing loss
• diagnostic tests that help differentiate sensory, neural, synaptic, and central processing disorders, that may inform applicability and outcomes for current or future hearing restoration therapeutics.
• develop reliable in-vitro human models to facilitate the understanding, derivation and characterization of human auditory cells, and/or to facilitate the evaluation of hearing restoration therapies.
• develop and/or validate techniques/methods beyond the audiogram to diagnose acute auditory system injury in austere or remote environments.  for example, but not limited to, simple and rapid assessments that are compatible with portable platforms.

https://cdmrp.army.mil/funding/hrrp

focused research award – preproposal due july 14, 2020

independent investigators at all academic levels (or equivalent)

• preproposal is required; application submission is by invitation only.
• supports promising research that will accelerate drug discovery and therapeutic development for hearing restoration or accelerate advances in the assessment, diagnostics, and treatment of auditory dysfunction.
• must address one or more of the fy20 hrrp focus areas.
• funding level 1 supports exploratory, high-risk/high-reward research in the earliest stages of development.
• funding level 2 supports the advancement of more mature research toward clinical translation.
• funding level 2 may include a pilot clinical trial component where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.
• it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the stage and maturity of the research, rather than the amount of the budget.
• tinnitus or vestibular-related research is excluded.

funding level 1:

• maximum funding of $250,000 for direct costs (plus indirect costs)
  • the maximum period of performance is 2 years.

funding level 2:

• maximum funding of $1,000,000 for direct costs (plus indirect costs)
  • the maximum period of performance is 3 years.

funding level 2 with pilot clinical trial option:

• maximum funding of $1.250,000 for direct costs (plus indirect costs)
• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the hrrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriation act provides $16 million to the department of defense neurotoxin exposure treatment parkinson’s program (netp) to support research to better understand and treat the neuro-degenerative effects of parkinson’s disease (pd) associated with military deployment, environmental, and/or occupational exposures.  research into military service-related risk factors is critical for past, present, and future service members who may be affected pd. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcement/funding opportunity is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 netp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy20 netp must address at least one of the following focus areas:

• quantifiable gene - environment interactions and the risk for or progression of parkinson’s disease.  though not limited to this list, the following are some examples of areas that are encouraged:

○        genome wide genotyping/sequencing of existing cohorts (must include data sharing plan)

○        environmental exposures (toxins, medications, dietary, caffeine, among others)

○        unbiased screens with biological validation

• basic biology of non-motor symptoms that could lead to the development of new treatments for parkinson’s disease following neurotoxin exposure.  though not limited to this list, the following are some examples of areas that are encouraged:

○        sleep

○        cognition (relevant to pd)

○        psychiatric dysfunction

○        autonomic dysregulation

• system-level mechanism of dopamine refractory motor symptoms in parkinson’s disease, including postural instability, freezing of gait, and treatment-associated dystonia, that could lead to development of new treatments in patients with neurotoxin exposure.  though not limited to this list, the following are some examples of approaches that could be used:

○        circuitry

○        pathophysiology 

○        neurochemistry

• clinical and research application of digital health technology leading to development of new treatments for parkinson’s disease in those individuals exposed to neurotoxins.

○        early identification

○        innovative data analytic methods

○        disease subtyping

https://cdmrp.army.mil/funding/netp

investigator-initiated research award – letter of intent due august 18, 2020

assistant professor level or above (or equivalent)

supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to neurotoxin exposure- and treatment-related parkinson’s research. this award mechanism supports the full spectrum of research from basic science through clinical research.

• must address at least one of the fy20 netp focus areas.
• preliminary data to support feasibility are encouraged.
• submission of a letter of intent is required prior to full application submission.
• clinical trials are not allowed
• maximum funding of $1.2 million (m) for total costs (includes direct and indirect costs)
• maximum period of performance is 3 years

early investigator research award – letter of intent due august 18, 2020

investigator must be a postdoctoral or clinical fellow, instructor, or assistant professor within 10 years of advanced degree or residency training (or equivalent)

supports neurotoxin exposure- and treatment-related parkinson’s research opportunities for individuals in the early stages of their careers, under the guidance of a designated mentor.

• pis must have a designated mentor who is an experienced parkinson’s disease researcher.
• must address at least one of the fy netp focus areas.
  • preliminary data are not required
  • clinical trials are not allowed
  • submission of a letter of intent is required prior to full application submission.
  • maximum funding of $400,000 i for total costs (includes direct and indirect costs)
  • maximum period of performance 2 years

synergistic idea award – letter of intent due august 18, 2020

assistant professor level or above (or equivalent).

• supports new ideas that represent synergistic approaches to  neurotoxin exposure- and treatment-related parkinson’s research involving two to four faculty-level (or equivalent) principal investigators (pis).
• the combined efforts of the pis should utilize their complementary and synergistic perspectives to address a central problem or question in neurotoxin exposure- and treatment-related parkinson’s research.
• designed to support both new and pre-existing partnerships, and encourages participation of pis from other research fields.
• must address at least one for the fy20 netp focus areas..
• preliminary data are not required
• submission of a letter of intent is required prior to full application submissions.
• clinical trials are not allowed
  • maximum funding of $3million (m) for total costs (includes direct and indirect costs)
  • maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the netp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. please note that partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

connection grants are expected to respond to the objectives of the connection program.

these grants support events and outreach activities geared toward short-term, targeted knowledge mobilization initiatives. these events and activities represent opportunities to exchange knowledge and to engage on research issues of value to those participating. events and outreach activities funded by a connection grant may often serve as a first step toward more comprehensive and longer-term projects.

connection grants support workshops, colloquiums, conferences, forums, summer institutes, or other events or outreach activities that facilitate:

• disciplinary and/or interdisciplinary exchanges in the social sciences and humanities;
• scholarly exchanges between those working in the social sciences and humanities and those working in other research fields;
• intersectoral exchanges between academic researchers in the social sciences and humanities and researchers and practitioners from the public, private and/or not-for-profit sectors; and/or
• international research collaboration and scholarly exchanges with researchers, 世界杯2022赛程表淘汰赛 and non-academic partners from other countries.

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. please note that partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and post secondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

the objective of the idea to innovation (i2i) grants is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established canadian company. the i2i grants provide funding to college and university faculty members to support research and development projects with recognized technology transfer potential. this is achieved through defined phases by providing crucial assistance in the early stages of technology validation and market connection.